PDS Biotechnology updates corporate presentation; no financial or clinical data disclosed

PDS Biotechnology Corp

Filed 8-K on June 25, 2025, with updated corporate presentation as Exhibit 99.1.
Presentation titled 'Addressing the Growing Incidence of HPV16-Related Cancers' and 'Precision Designed Science For Immunotherapy'.
No new financial results, clinical trial data, or guidance provided in the filing.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.